Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming

Abstract

Background Adiponectin, the most abundant adipokine derived from adipose tissue, exhibits a potent suppressive effect on the growth of breast cancer cells; however, the underlying molecular mechanisms for this effect are not completely understood. Fatty acid metabolic reprogramming has recently been recognized as a crucial driver of cancer progression. Adiponectin demonstrates a wide range of metabolic activities for the modulation of lipid metabolism under physiological conditions. However, the biological actions of adiponectin in cancer-specific lipid metabolism and its role in the regulation of cancer cell growth remain elusive. Methods The effects of adiponectin on fatty acid metabolism were evaluated by measuring the cellular neutral lipid pool, free fatty acid level, and fatty acid oxidation (FAO). Colocalization between fluorescent-labeled lipid droplets and LC3/lysosomes was employed to detect lipophagy activation. Cell viability and apoptosis were examined by MTS assay, caspase-3/7 activity measurement, TUNEL assay, and Annexin V binding assay. Gene expression was determined by real time-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The transcriptional activity of SREBP-1 was examined by a specific dsDNA binding assay. The modulatory roles of SIRT-1 and adiponectin-activated mediators were confirmed by gene silencing and/or using their pharmacological inhibitors. Observations from in vitro assays were further validated in an MDA-MB-231 orthotopic breast tumor model. Results Globular adiponectin (gAcrp) prominently decreased the cellular lipid pool in different breast cancer cells. The cellular lipid deficiency promoted apoptosis by causing disruption of lipid rafts and blocking raft-associated signal transduction. Mechanistically, dysregulated cellular lipid homeostasis by adiponectin was induced by two concerted actions: 1) suppression of fatty acid synthesis (FAS) through downregulation of SREBP-1 and FAS-related enzymes, and 2) stimulation of lipophagy-mediated lipolysis and FAO. Notably, SIRT-1 induction critically contributed to the adiponectin-induced metabolic alterations. Finally, fatty acid metabolic remodeling by adiponectin and the key role of SIRT-1 were confirmed in nude mice bearing breast tumor xenografts. Conclusion This study elucidates the multifaceted role of adiponectin in tumor fatty acid metabolic reprogramming and provides evidence for the connection between its metabolic actions and suppression of breast cancer.

Exploring the causality and pathogenesis of systemic lupus erythematosus in breast cancer based on Mendelian randomization and transcriptome data analyses

“…We noticed that the genomic difference exhibited a significant correlation with cancer or cell cycle-related pathways, including metabolic pathways, transcriptional mis-regulation, and fatty acid biosynthesis. These findings were consistent with some earlier prior studies in which the presence of aberrant transcription (37) or fatty acid metabolic reprogramming (38) was ascertained to be a crucial driver of breast cancer progression. The PPI network further introduced the top twenty molecules, which exhibited substantially close interactions in breast cancer.…”

Anti-inflammatory effect of a triterpenoid from Balanophora laxiflora: results of bioactivity-guided isolation

“…Cell viability assay was carried out as described previously ( Pham and Park 2022 ). In brief, Raw 264.7 cells were seeded in 96-well plates at the density of 5×10 4 cells/well.…”

Targeting Adiponectin in Breast Cancer

“…In the same concept, an in vivo study showed that adiponectin treatment inhibits leptin-induced mammary tumorigenesis in nude mice by suppressing two canonical signaling molecules, extracellular signal-regulated kinase (ERK) and Akt [ 42 ]. Furthermore, a recent study showed that globular adiponectin induces tumor suppression by decreasing the cellular lipid pool, mainly through the inhibition of fatty acid synthase (FAS) and the activation of Sirtuin 1 (SIRT-1), which will promote apoptosis in vivo and in vitro [ 78 ].…”